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This study aimed to evaluate the utility of the pleural fluid lactate dehydrogenase (LDH) isoenzyme algorithm for 
the differential diagnosis of pleural fluid in patients with haematological malignancies. 
Twenty consecutive haemato-oncological patients with pleural effusion, hospitalized in the Haematology 
Department during a 2.75-year period, were prospectively and independently evaluated for the cause of effusion by 
standard methods and the LDH isoenzyme algorithm. The causes of the pleural effusions established during the 
standard evaluations were compared to the results obtained from the LDH isoenzyme algorithm. 
Following the standard evaluation, the pleural effusion was attributed to congestive heart failure in one patient, 
to infection in six, to the underlying malignancy in 12 and to concomitant congestive heart failure and malignancy 
in one. LDH isoenzyme analysis correctly predicted the cause of pleural effusion in 18 patients (positive predictive 
value 90%). 
In haemato-oncological patients, the pleural fluid LDH isoenzyme pattern may be helpful in the differential 
diagnosis of the most common causes of pleural effusion. 
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Introduction 
Haemato-oncological patients frequently have diverse 
pulmonary complications, including infections, haemor- 
rhage, leukaemic or lymphomatous lung involvement, 
adverse drug reactions and disease processes unrelated to 
their malignancy (1,2). Lymphomas, including Hodgkin’s 
disease (HD) and non-Hodgkin’s lymphoma (NHL), are 
the third leading cause of malignant pleural effusions (3). 
About 16% of patients with either HD or NHL and 4% of 
patients with acute myeloid leukaemia (AML) develop 
pleural effusions (4). Although usually these effusions are 
attributed to the underlying malignancy, other aetiologies, 
such as infections and congestive heart failure (CHF), may 
be responsible for pleural fluid accumulation. Pleural fluid 
cytology and pleural biopsy are considered to be the 
gold-standards for the diagnosis of malignant effusions. 
However, these are positive in only 77% of malignant 
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effusions (5). Moreover, pleural fluids frequently contain 
few morphologically recognizable malignant cells so that 
even the most experienced cytologists are unable to render 
a definitive diagnosis. 
In a previous study (6) we demonstrated the utility of 
pleural lactate dehydrogenase (LDH) isoenzyme analysis 
for the diagnosis of pleural effusion in unselected patients. 
In the present study we have prospectively evaluated the 
utility of pleural LDH isoenzyme analysis in consecutive 
haematological patients. 
Methods 
The study population consisted of 20 consecutive patients 
(13 men and seven women) who were hospitalized in 
the Haematology Department of Hadassah University 
Hospital in Jerusalem during the period from June 1995 
to March 1998. All patients had previously diagnosed 
haematological malignancy and presented with a new 
pleural effusion. The underlying malignancy in these 
patients was NHL in 12 patients, HD in two, AML in 
four, chronic lymphocyte leukaemia (CLL) in one and 
Waldenstrom macroglobulinaemia in one. All patients were 
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FIG. 1. Classification and regression tree for pleural effusion analysis based on total and isoenzyme pattern of lactate 
dehydrogenase (LDH) measurements. Total pleural LDH activity is expressed in units (normal serum is 100&300 U). LDH 
isoenzymes are expressed as relative percentages of total pleural LDH. 
prospectively evaluated by medical history and complete 
physical examination, blood tests, chest radiographs, CT 
scans and bone marrow biopsy and aspiration. Pleural fluid 
obtained by thoracocentesis was evaluated for levels of 
glucose, protein, LDH, LDH isoenzyme, pH, bacterio- 
logical studies (including Ziehl-Neelsen stain and myo- 
bacterial cultures) and cytological studies. Pleural effusions 
were categorized into transudate or exudate according to 
total protein and LDH levels. Whenever appropriate, other 
studies including flow cytometry and immunoglobulin 
gene rearrangements, echocardiography, fibre-optic 
bronchoscopy and transthoracic pleural and lung biopsies 
were performed to establish the cause of the effusion. 
The effusion was attributed to CHF if the patient 
had abnormal heart function demonstrated by echo- 
cardiography, normal results of microbiological and cyto- 
logical studies, was afebrile and improved with appropriate 
anti-CHF therapy. Pneumonia-related effusions included 
empyema and parapneumonic effusions. All patients with 
pneumonia-related effusions had positive sputum, blood or 
pleural fluid microbiological cultures. Malignant effusion 
was defined as effusions with: malignant cells or compatible 
pleural fluid flow cytometry or monoclonal immuno- 
globulin gene rearrangement, or when due to atelectasis 
or mediastinal lymphadenopathy in association with histo- 
logically proved lung involvement by the underlying 
haematological malignancy. 
The categorization of patients into the diagnostic groups 
according to the above criteria was performed without the 
knowledge of the LDH isoenzyme results. Concomitantly, 
one of us (I.S.L.), who was unaware of the results of all the 
standard diagnostic tests, prospectively predicted the cause 
of the pleural effusion based solely on the results of pleural 
LDH isoenzyme analysis according to the previously 
published algorithm (Fig. 1) (6). 
LDH isoenzymes were determined by an LDH isoenzyme 
electrophoresis kit (p/N 655940, Beckman Instruments, 
Fullerton, CA, U.S.A.) and expressed as a percentage of the 
total LDH activity. The normal serum range of LDH 
activities is 100-300 U. 
Results 
During the study period, 20 patients were evaluated for the 
cause of the new pleural effusion. In all patients the effusion 
was unilateral, The clinical characteristics of the patients, 
the results of the LDH isoenzyme analysis and the 
aetiologies of pleural effusions are presented in Table 1. 
Using standard pleural fluid evaluation, effusions were 
found to be caused by the underlying haematological 
malignancy in 12 patients, infection in six, CHF in one and 
concomitant CLL and CHF in one. Pleural fluid cytology 
was positive in two of the 12 patients with malignant 
effusion. In the remaining four patients, the diagnosis was 
established by the presence of IgM paraprotein and mono- 
clonal gene rearrangement of effusion cells in a patient with 
Waldenstrom macroglobulinaema, by transthoracic lung 
biopsy in two patients with NHL and by mediastinal biopsy 
of chloroma in one patient with AML. 
Using LDH isoenzyme analysis, the cause of pleural 
effusion was correctly predicted in 18 patients (positive 
predictive value 90%). It missed the diagnosis in one patient 
with malignant pleural effusion attributed to Waldenstrom 
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TABLE 1. Clinical characteristics of pleural LDH isoenzyme analysis 
Pleural fluid 
Total LDH, LDH, LDH, LDH, LDH, Cause of 
Basic malignancy LDH WI (%I (%I (%I (%) Exudate pleural effusion 
HD 9139 2.7 9.8 19.9 26.0 41.6 + Empyema 
HD 719 10.1 18.1 14.1 19.2 38.5 + HD 
NHL 833 19.5 37.2 23.1 11.7 8.5 + NHL 
NHL 184 3.5 10.4 18.7 25.9 41.5 + Pneumonia 
NHL 372 16.3 30.0 22.1 16.1 15.5 + NHL 
NHL 17 392 24 9.0 16.6 27.3 44.7 + Empyema 
NHL 1886 13.2 24.6 20.8 14.9 26.6 + NHL 
NHL 725 4.4 10.1 19.1 26.7 39.8 + Pneumonia 
NHL 260 13.8 32.3 29.1 15.2 9.5 + NHL 
NHL 248 18.8 45.1 23.1 7.6 5.4 + NHL 
NHL 534 14.7 27.6 22.5 19.3 15.9 + NHL 
NHL 350 8.5 21.9 22.0 11.9 35.7 + NHL 
NHL 650 11.0 30.6 27.6 11.9 13.9 + NHL 
NHL 2567 5.3 21.0 27.5 17.1 29.1 + NHL 
WM” 160 7.7 17.6 25.2 21.2 28.4 + WM 
CLLT 100 19.2 39.7 22.8 8.6 9.7 - CLL+CHF 
AML 1897 4.6 13.6 20.2 26.8 35.2 + Pneumonia 
AML 318 7.6 12.7 19.3 28.6 31.8 + Pneumonia 
AML 308 11.4 21.3 17.4 21.6 28.2 + AML 
AML 178 11.3 22.1 16.8 22.6 27.3 + CHF 
HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; AML, acute myeloid leukaemia; CLL, 
chronic lymphocytic leukaemia; WM, Waldenstrom macroglobulinaemia. 
*Patient whose cause of pleural effusion was misdiagnosed by LDH isoenzyme analysis. 
j-Patient whose pleural effusion was caused by concomitant CHF and CLL, while LDH isoenzyme 
analysis predicted only CLL. 
macroglobulinaemia. In another patient with CLL, the 
pleural effusion was caused by concomitant malignancy and 
an underlying CHF. In this patient the algorithm predicted 
only malignancy. 
Discussion 
LDH is expressed as five isoenzymes, having different 
distributions in various tissues. It has been shown that the 
pleural LDH isoenzyme pattern differs from that in serum 
(7). In our previous study, we demonstrated that analysis of 
the pleural LDH isoenzyme pattern may be helpful in 
diagnosing the cause of pleural effusion in an unselected 
cohort of patients (6). By applying the classification and 
regression tree method (CART) (8), a decision tree was 
established with a positive predictive value of 83%. In the 
present study, we have prospectively evaluated the utility of 
this decision tree in a cohort of hospitalized haemato- 
oncological patients not included in our previous study (6). 
The present study demonstrates that this algorithm is 
applicable in this population with a positive predictive 
value of 90%. 
In NHL and HD, possible mechanisms for the formation 
of pleural effusion include: (a) pleural infiltration by 
tumour with shedding of cells into the pleural space; (b) 
lymphatic obstruction by lymphomatous infiltration of 
pulmonary lymphatics with resultant ‘lymphoedema’ of the 
pleural space; and (c) obstruction of the thoracic duct which 
leads to chylothorax. Although some studies have claimed 
that malignant pleural infiltration is the most common 
cause of pleural effusion in lymphoma (9), others have 
suggested that lymphatic obstruction due to mediastinal 
adenopathy is more common (10). Similar mechanisms 
may be applicable to the formation of pleural effusion in 
leukaemic patients. In addition to pleural effusion due to 
the underlying malignancy, it may also be caused by CHF, 
pneumonia and other more rare disorders. 
Cytology is considered the gold-standard for the diag- 
nosis of malignant pleural effusions. Positive cytology 
is reported in 14-88% of patients with lymphomatous 
effusions (10,ll). Moreover, the effusion frequently con- 
tains only a few morphologically recognizable malignant 
cells so that cytology is unable to render a definitive 
diagnosis. In CLL and small lymphocytic NHL, the 
malignant lymphocytes in pleural effusion cannot be cyto- 
logically distinguished from chronic inflammatory cells, 
thus further ‘limiting the diagnostic utility of cytology in 
these cases (11). 
In our previous study (6), LDH isoenzyme pattern 
correctly predicted malignancy in 82% of patients with 
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cytologically positive malignant effusions and in 83% with 
malignancy and cytologically negative effusions. In the 
present study, cytology was positive in only nine of the 13 
patients with malignant effusion; while LDH isoenzyme 
pattern correctly predicted malignancy in 12 of these 
patients. Therefore, LDH isoenzyme analysis may preclude 
the necessity for a more invasive procedure (i.e. lung or 
pleural biopsy) in cytologically negative effusions. Further- 
more, LDH isoenzyme analysis is helpful in the diagnosis of 
other causes - infections and CHF. 
LDH isoenzyme analysis requires small volume samples. 
It is quick, easy to perform and not expensive, in contrast to 
the more expensive and time-consuming flow cytometry 
and gene rearrangement studies. The commonly used 
criteria of Light et al. (12) for the differentiation of pleural 
effusion establish the exudative or transudative nature of 
the pleural fluid but do not determine its specific aetiology. 
Although the majority of pleural effusions attributive to 
CHF are transudates, exudates are also encountered (13). 
Similarly, not all malignant effusions are exudates. Our 
decision tree enables a specific diagnosis of the most 
common causes of pleural effusion without relying on their 
transudativelexudative nature. 
In conclusion, in haemato-oncological patients, the LDH 
isoenzyme pattern may be useful in the differential diag- 
nosis of pleural effusion and may contribute to cytological 
studies of pleural fluid, suggesting a malignant aetiology 
even in cytologically negative neoplastic pleural effusions. 
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